2,5-Dimethoxyamphetamine

Use and effects

2,5-DMA is said to be inactive as a psychedelic, at least at the doses that have been assessed. However, it has been reported to produce some stimulant-like effects, as well as sympathomimetic effects and mydriasis. The dose range is said to be 80 to 160mg orally and its duration is 6 to 8hours. However, it has also been said to be active with stimulant-like effects at a dose of 50mg.

Interactions

Pharmacology

Pharmacodynamics

2,5-DMA is a low-potency serotonin 5-HT2A receptor partial agonist, with an affinity (Ki) of 2,502nM, an of 160 to 3,548nM (depending on the signaling cascade and study), and an of 66 to 109%. It has also been assessed at several other receptors. In a much earlier study, its affinities (Ki) were 1,020nM at the serotonin 5-HT1 receptor and 5,200nM at the serotonin 5-HT2 receptor. The drug does not appear to bind to the monoamine transporters, at least at the assessed concentrations (up to 7,000nM). It was inactive at the human trace amine-associated receptor 1 (TAAR1). 2,5-DMA shows dramatically reduced potency as a serotonin 5-HT2A receptor agonist compared to the DOx drugs, such as 2,5-dimethoxy-4-methylamphetamine (DOM).

2,5-DMA produces the head-twitch response, a behavioral proxy of psychedelic effects, in rodents. However, it produces a very weak head-twitch response compared to other structurally related psychedelics like DOM, DOET, DOPR, and even DOBU. In addition, it is less potent in comparison. 2,5-DMA substitutes for DOM in rodent drug discrimination tests, albeit with dramatically lower potency than other DOx drugs. It also substitutes for 5-MeO-DMT in rodent drug discrimination tests. These findings suggesting that 2,5-DMA might produce weak hallucinogenic effects at sufficiently high doses. 2,5-DMA shows no substitution for dextroamphetamine in drug discrimination tests, suggesting that it lacks psychostimulant- or amphetamine-like effects, at least in rodents. Unlike other DOx drugs like DOM, DOPR, DOBU, and DOAM, 2,5-DMA does not produce hyperlocomotion in rodents and instead dose-dependently produces only hypolocomotion. On the other hand, it does similarly produce hypothermia at higher doses.

Though 2,5-DMA appears to be inactive or of very low potency as a psychedelic in humans, it is a highly potent anti-inflammatory drug similarly to other DOx and 2C drugs. This was in spite of it being of very low potency as a serotonin 5-HT2A receptor agonist in terms of calcium mobilization in the study (EC50 = 3,548nM; Emax = 109.0%). Based on the preceding findings, Charles D. Nichols has said that both fully anti-inflammatory non-psychedelic compounds like 2,5-DMA and fully psychedelic non-anti-inflammatory compounds like DOTFM are known.

Pharmacokinetics

2,5-DMA crosses the blood–brain barrier in rodents. It showed the lowest brain/plasma ratio among DOM and its higher homologues.

Chemistry

Synthesis

The chemical synthesis of 2,5-DMA has been described.

Analogues and derivatives

Analogues and derivatives of 2,5-DMA include the DOx series like DOM, DOB, and DOI, FLY compounds like DOB-FLY, Bromo-DragonFLY (DOB-DFLY), DOH-5-hemiFLY, 25-NB compounds like DOM-NBOMe, DOB-NBOMe, and DOI-NBOMe, and other compounds like trimethoxyamphetamines (TMAs) and pentamethoxyamphetamine (PeMA).

History

2,5-DMA was first described in the scientific literature by F. Benington and colleagues by at least 1968. Subsequently, it was described in greater detail by Alexander Shulgin in his 1991 book PiHKAL (Phenethylamines I Have Known and Loved).

Society and culture

Manufacturing

2,5-DMA is used by Polaroid Corporation in the manufacturing of Polaroid film.

Legal status

Canada

2,5-DMA is a controlled substance in Canada.

United States

2,5-DMA is a schedule I controlled substance in the United States.

References

References

1. (1991). "[[PiHKAL: A Chemical Love Story]]". Transform Press.
2. (2011). "[[The Shulgin Index". Transform Press.
3. (15 March 2025). "Kᵢ Database".
4. "BindingDB BDBM50005251 (+/-)2-(2,5-Dimethoxy-phenyl)-1-methyl-ethylamine::1-(2,5-dimethoxyphenyl)propan-2-amine::2,5-dimethoxy-4-bromoamphetamine::2-(2,5-Dimethoxy-phenyl)-1-methyl-ethylamine::2-(2,5-Dimethoxy-phenyl)-1-methyl-ethylamine(2,5-DMA)::CHEMBL8642::DMA".
5. (January 1999). "Comparisons of hallucinogenic phenylisopropylamine binding affinities at cloned human 5-HT2A, -HT(2B) and 5-HT2C receptors". Naunyn-Schmiedeberg's Archives of Pharmacology.
6. (November 2025). "The 4-alkyl chain length of 2,5-dimethoxyamphetamines differentially affects in vitro serotonin receptor actions versus in vivo psychedelic-like effects". Mol Psychiatry.
7. (2023). "Binding and functional structure-activity similarities of 4-substituted 2,5-dimethoxyphenyl isopropylamine analogues at 5-HT_2A and 5-HT_2B serotonin receptors". Frontiers in Pharmacology.
8. (August 2000). "1-[4-(3-Phenylalkyl)phenyl]-2-aminopropanes as 5-HT(2A) partial agonists". Journal of Medicinal Chemistry.
9. (June 2002). "Differences in potency and efficacy of a series of phenylisopropylamine/phenylethylamine pairs at 5-HT(2A) and 5-HT(2C) receptors". British Journal of Pharmacology.
10. (November 2008). "Potential modes of interaction of 9-aminomethyl-9,10-dihydroanthracene (AMDA) derivatives with the 5-HT2A receptor: a ligand structure-affinity relationship, receptor mutagenesis and receptor modeling investigation". Journal of Medicinal Chemistry.
11. (2019). "Amphetamine Derivatives as Monoamine Oxidase Inhibitors". Frontiers in Pharmacology.
12. (2022). "Monoamine Receptor and Transporter Interaction Profiles of 4-Alkyl-Substituted 2,5-Dimethoxyamphetamines". The FASEB Journal.
13. (2022). "Structure-activity Relation of Halogenated 2,5-Dimethoxyamphetamines Compared to their α‑Desmethyl (2C) Analogues". The FASEB Journal.
14. (October 2020). "In vitro structure-activity relationship determination of 30 psychedelic new psychoactive substances by means of β-arrestin 2 recruitment to the serotonin 2A receptor". Archives of Toxicology.
15. (January 1987). "Central serotonin receptors as targets for drug research". Journal of Medicinal Chemistry.
16. (June 1984). "5-HT1 and 5-HT2 binding properties of derivatives of the hallucinogen 1-(2,5-dimethoxyphenyl)-2-aminopropane (2,5-DMA)". European Journal of Pharmacology.
17. (1989). "Stimulus properties of hallucinogenic phenalkylamines and related designer drugs: formulation of structure-activity relationships". NIDA Research Monograph.
18. (1980). "Hallucinogenic agents as discriminative stimuli: a correlation with serotonin receptor affinities". Psychopharmacology.
19. (April 2021). "Structure-Activity Relationship Analysis of Psychedelics in a Rat Model of Asthma Reveals the Anti-Inflammatory Pharmacophore". ACS Pharmacology & Translational Science.
20. (14 November 2021). "PODCAST 33: An interview with Dr. Charles D. Nichols". Patreon.
21. (2013). "Phenethylamine: von der Struktur zur Funktion". Nachtschatten-Verlag.
22. (July 1968). "The chemorelease of norepinephrine from mouse hearts by substituted amphetamines". J Med Chem.
23. (February 1969). "Structure--activity relationships of one-ring psychotomimetics". Nature.
24. (1978). "Stimulants". Springer US.
25. "Erowid Psychoactive Vault : DEA Federal Register".
26. (25 April 2000). "Manufacturer of Controlled Substances; Notice of Registration".
27. "Controlled Drugs and Substances Act".
28. (January 2026). "Orange Book: List of Controlled Substances and Regulated Chemicals (January 2026)". U.S. [[Department of Justice]]: [[Drug Enforcement Administration]] (DEA): Diversion Control Division.